Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.11, Bloomberg Earnings reports.

Madrigal Pharmaceuticals (MDGL) traded down $0.64 during midday trading on Friday, reaching $44.08. 85,641 shares of the company’s stock traded hands, compared to its average volume of 41,823. Madrigal Pharmaceuticals has a 12 month low of $13.09 and a 12 month high of $52.35.

WARNING: “Madrigal Pharmaceuticals, Inc. (MDGL) Issues Quarterly Earnings Results” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/10/madrigal-pharmaceuticals-inc-mdgl-issues-quarterly-earnings-results.html.

MDGL has been the subject of several analyst reports. Evercore ISI initiated coverage on shares of Madrigal Pharmaceuticals in a report on Friday, September 22nd. They set an “outperform” rating and a $65.00 price target for the company. JMP Securities boosted their price target on shares of Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the stock an “outperform” rating in a report on Friday, October 13th. Finally, Roth Capital initiated coverage on shares of Madrigal Pharmaceuticals in a report on Thursday, October 19th. They set a “buy” rating and a $62.00 price target for the company.

In related news, Director Richard S. Levy acquired 2,000 shares of Madrigal Pharmaceuticals stock in a transaction dated Wednesday, August 23rd. The stock was acquired at an average price of $16.12 per share, for a total transaction of $32,240.00. Following the transaction, the director now owns 7,200 shares of the company’s stock, valued at $116,064. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard S. Levy acquired 3,550 shares of Madrigal Pharmaceuticals stock in a transaction dated Monday, August 21st. The shares were bought at an average price of $15.88 per share, with a total value of $56,374.00. Following the transaction, the director now directly owns 900 shares in the company, valued at approximately $14,292. The disclosure for this purchase can be found here. Insiders have acquired a total of 9,100 shares of company stock valued at $145,840 in the last quarter. 66.40% of the stock is currently owned by company insiders.

A hedge fund recently bought a new stake in Madrigal Pharmaceuticals stock. State Street Corp acquired a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 33,170 shares of the biopharmaceutical company’s stock, valued at approximately $539,000. State Street Corp owned about 0.27% of Madrigal Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 16.86% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

Earnings History for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Stock Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.